579. Clinical and Drug Resistance Characteristics of Providencia spp. Infections

BACKGROUND: Providencia is a gram-negative bacillus that colonizes the urinary tract and is often resistant to many antimicrobials. This study aimed to evaluate resistance patterns of Providencia spp (P. spp) and clinical outcomes due to the paucity of topical data. METHODS: A multi-center, descriptive, retrospective chart review of adult patients with P. spp. infections was conducted from January 1, 2020 to May 31, 2022. The primary outcome was to describe the drug resistance patterns of P. spp. isolates. The study’s secondary outcome was to evaluate the clinical outcomes of patients with P. spp infections. RESULTS: Of 312 patients screened, 243 were excluded primarily for polymicrobial infections. The mean age was 70 years and 39 (56.5%) were males. Of the 69 included cases, 46 (66.7%) were P. stuartii, 21 (30.4%) P. rettgerri, and 2 (2.9%) P. alcalifaciens. The most common infections were bacteremia 38 (55.1%), with urinary and wound being the most frequent bacteremia source; followed by 28 (40.6%) urinary tract and 3 (4.3%) wound infections. 45 patients (65.2%) had urinary catheters. Primary antibiotics used for treatment consisted of ceftriaxone, 25 (36.2%), cefepime, 20 (29%), and meropenem, 10 (14.5%). Five of 69 (7.2%) cases were multidrug resistant and required meropenem. Nineteen patients (27.1%) died during their admission but none related to Providencia infections. Ten of the 69 patients (14.5%) were readmitted within 30 days for reasons unrelated to progression or recurrence of Providencia infections. CONCLUSION: Providencia bacteremia was the most common infection. Third generation cephalosporins remain an appropriate choice of antibiotics for P. spp. However, P. stuartii was the only species with multidrug resistance. Future studies should be carried out to confirm this observation. DISCLOSURES: All Authors: No reported disclosures